{"doi":"10.1111/jvim.16041","title":"Retrospective analysis of the effects of <i>Blastomyces</i> antigen concentration in urine and radiographic findings on survival in dogs with blastomycosis","abstract":"BACKGROUND: The Blastomyces antigen concentration in urine (BACU) test is used to diagnose blastomycosis and monitor treatment in dogs. It is unknown if a higher BACU is associated with shorter survival. OBJECTIVES: To determine if the magnitude of BACU before treatment is associated with survival in dogs with blastomycosis. ANIMALS: Fifty-two dogs with blastomycosis. METHODS: Retrospective case review. BACU, radiographic lung severity (RLS) score (0-4 scale), and survival time up to 1 year after diagnosis were obtained through medical record review of dogs with Blastomyces dermatitidis. RESULTS: = 0.33, P = .02). BACU and RLS scores were lower in survivors to 2 months than nonsurvivors (average BACU difference of 2.5 ng/mL, 95% confidence interval [CI]: 0.2-4.8 ng/mL, P = .04; median RLS difference of 2; range, 0-4, P = .02). Dogs with BACU <5 ng/mL and dogs with mild (0-1) RLS scores had a greater proportion surviving than those with BACU >5 ng/mL (P = .03) and dogs with severe (3-4) RLS scores (P = .04). All dogs with a BACU <5 ng/mL or mild RLS score were alive at last follow-up (median, 365 days; range, 44-365 days). In all, 68.1% of other dogs survived to 2 months (95% CI, 54.8%-84.8%). CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with lower BACU and RLS scores have improved survival; however, it is unclear what specific cutoffs should be used for prognosis.","journal":"Journal of Veterinary Internal Medicine","year":2021,"id":203281,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9001,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":385988,"name":"Eva Furrow","orcid":"0000-0002-7339-2354","position":1,"is_corresponding":false},{"id":375677,"name":"Aaron Rendahl","orcid":"0000-0001-5434-3592","position":2,"is_corresponding":false},{"id":784012,"name":"Esther Nell","orcid":"0000-0002-3511-3174","position":3,"is_corresponding":false},{"id":784471,"name":"Kari L. Anderson","orcid":null,"position":4,"is_corresponding":false},{"id":763956,"name":"Lindsay K. Merkel","orcid":null,"position":5,"is_corresponding":false},{"id":287235,"name":"Edward E. Patterson","orcid":null,"position":6,"is_corresponding":false},{"id":784011,"name":"Laura O. Motschenbacher","orcid":"0000-0001-9622-6490","position":0,"is_corresponding":true}],"reference_count":10,"raw_metadata":null,"created_at":"2026-07-18T23:51:14.206397Z","pmid":"33604957","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}